TBI

Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

Retrieved on: 
Wednesday, April 3, 2024
Discovery, Epilepsy, GABAB, Senior, Glutamic acid, Dyskinesia, Glutamate (neurotransmitter), Drug discovery, Partnership, TBI, SIX, Chronic cough, NAM, CHF5, Therapy, DSM-IV codes, Janssen, Safety, ADX71149, Allosteric regulation, Janssen Pharmaceuticals, Dipraglurant, Research fellow, PAM, Pharmaceutical industry

With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix will acquire a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex and accelerate their development.

Key Points: 
  • With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix will acquire a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex and accelerate their development.
  • In return, Addex will receive CHF5 million and a 20% equity interest in Neurosterix.
  • “The launch of Neurosterix in partnership with Perceptive is an important validation of the Addex allosteric modulator drug discovery technology platform and provides the resources to accelerate development of important preclinical assets, including the M4 PAM and mGlu7 negative allosteric modulator (NAM) programs, into the clinic,” said Tim Dyer, CEO of Addex.
  • To guide the launch of Neurosterix, Tim Dyer, in addition to his role at Addex, will assume the role of CEO of Neurosterix.

Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board

Retrieved on: 
Tuesday, April 2, 2024
Citadel, Depression, Department of Defence, National War College, Legislation, Government, Army Command, Veteran, Veterans' affairs, General counsel, Patient, Insomnia, Colonel, TBI, Policy, Senior counsel, University, Anxiety, Military personnel, Military, Traumatic brain injury, OGC, National Security Strategy, Private law, PTSD, Nursing

HOUSTON, TEXAS, April 02, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the appointment of former Acting General Counsel to the Department of Veterans Affairs, William (“Bill”) A. Hudson, Jr., to the Company’s Military & Government Advisory Board (“Advisory Board”).

Key Points: 
  • HOUSTON, TEXAS, April 02, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the appointment of former Acting General Counsel to the Department of Veterans Affairs, William (“Bill”) A. Hudson, Jr., to the Company’s Military & Government Advisory Board (“Advisory Board”).
  • Nexalin’s Advisory Board provides strategic advice and counsel to support the Company’s advancement of its non-invasive, frequency-based, deep-brain stimulation devices in U.S. military and government agencies.
  • Mr. Hudson is a partner in Tully Rinckey PLLC’s Washington, D.C. office where he focuses his practice on military, security clearance, and federal employment law.
  • Mark White, CEO of Nexalin Technology stated, “We are honored to welcome Col. Bill Hudson to the Military & Government Advisory Board.

electroCore Expands Intellectual Property Portfolio

Retrieved on: 
Tuesday, April 2, 2024
Vagus nerve, Central nervous system, Fibromyalgia, Patent, TBI, Anxiety, Software, United States patent law, ElectroCore, PTSD, Medical device

ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).

Key Points: 
  • ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).
  • The two patents were issued on April 2, 2024, and relate to electroCore’s non-invasive vagus nerve stimulation (nVNS) technology:
    US Patent No.
  • The therapy regimen comprises generating an electrical signal for approximately 5 minutes to 30 minutes.
  • The electrical impulses are bursts of 2 to 20 sinusoidal pulses.

Linklogis Announces 2023 Annual Results: Maintaining the Largest Market Share in China for 4 Consecutive Years

Retrieved on: 
Tuesday, March 26, 2024
Cloud, Transfer, Vietnamese, PDD, OPPO, Contribution, Standard Chartered, GPT, Intellectual property, Bank, Sustainalytics, Social responsibility, Multi, Risk assessment, Supply chain, SME, Share repurchase, Digital, Intelligence, ESG, TBI, Acquisition, AI, Ecology, ChatGPT, Development, Growth, Blockchain, KYC, Cross, CMMI, Infor, LDP, Cryptocurrency

Beijing, China, March 26, 2024 (GLOBE NEWSWIRE) -- On March 26, 2024, Linklogis Inc. (09959.HK, “Linklogis”), a leading supply chain finance technology solution provider in China, released its 2023 annual results.

Key Points: 
  • Beijing, China, March 26, 2024 (GLOBE NEWSWIRE) -- On March 26, 2024, Linklogis Inc. (09959.HK, “Linklogis”), a leading supply chain finance technology solution provider in China, released its 2023 annual results.
  • The board of directors of Linklogis proposes to pay a special dividend of HK$0.1 per share, totaling approximately HK$230 million.
  • Furthermore, the board expresses confidence in the company’s prospects and sustained growth in the future, and announces a share repurchase plan of up to US$100 million.
  • According to China Insights Consultancy, Linklogis held 20.9% market share, ranking No.1 in the third-party supply chain finance technology solutions providers in China for the fourth consecutive year.

Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office

Retrieved on: 
Wednesday, March 20, 2024
Research, Composition, Nerve, Innovation, Psychological trauma, University, P-1, Patent, Stroke, MDXX, TBI, Cell membrane, United States patent law, Traumatic brain injury, OTC, MDMA, Pharmaceutical industry

“The molecule has an excellent therapeutic window; it shows a strong pro-social signal at dosage levels far below racemic MDMA.

Key Points: 
  • “The molecule has an excellent therapeutic window; it shows a strong pro-social signal at dosage levels far below racemic MDMA.
  • P-1 was submitted to the USPTO through the Patent Prosecution Highway program, allowing for accelerated patent examination.
  • As the molecule is ready for pre-clinical and clinical development, the Company has elected to change its designation to APA-001.
  • In addition there is potential applicability for the fear disorders often discussed in the context of MDMA.”

Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”

Retrieved on: 
Wednesday, March 13, 2024
Diagnosis, Depression, Washington Convention Center, Government, Development, Veteran, Walter, Patient, Insomnia, Concussion, TBI, Anxiety, MTEC, Chronic pain, Traumatic brain injury, Dementia, PTSD, Medical device

HOUSTON, TEXAS, March 13, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced it was selected and provided a poster presentation at the “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment” on March 12, 2024, which was held at the Walter E. Washington Convention Center in Washington, D.C.

Key Points: 
  • The U.S. Army Medical Research and Development Command’s (USAMRDC) Combat Casualty Care Research Program (CCCRP) Neurotrauma Portfolio and the Biomedical Advanced Research and Development Authority (BARDA), with support of MTEC, hosted the State of the Technology meeting focused on non-invasive neuroassessment tools.
  • This was an ideal venue for our poster presentation as the conference attendees included many of the leading thought leaders and decision-makers from both the public and private sectors.
  • Notably, both the DoD and BARDA’s concerns continue to grow surrounding TBI, and we’re seeing the US Government significantly invest in new, non-drug therapeutic options to address TBI in support of struggling warfighters and veterans.
  • We could not have been more pleased with the overwhelming response to our presentation and look forward to providing more details on our latest study in an upcoming abstract publication.”

Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for AST-004

Retrieved on: 
Tuesday, March 12, 2024
Diagnosis, Stroke, Brain, Patient, Concussion, TBI, Death, IND, Traumatic brain injury, Investigational New Drug, Yale school, FDA, Health, Food, Pharmaceutical industry

The IND application clearance also paves the way for additional studies further exploring AST-004 in stroke, as well as TBI, and concussion.

Key Points: 
  • The IND application clearance also paves the way for additional studies further exploring AST-004 in stroke, as well as TBI, and concussion.
  • And it has the potential to treat stroke occurring in any sized blood vessel in the brain.
  • Astrocyte previously completed two Phase 1 safety trials in Europe, involving 80 participants in total, and saw no significant adverse effects or safety concerns.
  • Dr. William Korinek, CEO of Astrocyte Pharmaceuticals, commented, “Since our founding in 2014, we have been focused on demonstrating the potential of cerebroprotective benefits of AST-004.

Garnett Station Partners Launches Accident Care Alliance, a Specialized Accident Injury Healthcare Services Platform

Retrieved on: 
Tuesday, April 2, 2024
Automotive, Physical Therapy, Professional Services, Managed Care, Other Health, Health, General Health, Neurology, Other Automotive, Asset Management, Telemedicine, Virtual Medicine, Pain management, Chiropractic, Patient, Garnett station, Accident, TBI, ACA, Elective surgery, Health insurance

Garnett Station Partners (“Garnett Station”), a New York-based principal investment firm that manages over $2.3 billion of assets, today announced the launch of Accident Care Alliance (“ACA”), a highly specialized platform comprised of best-in-class healthcare providers focused on delivering holistic, individualized care for those injured primarily in automobile accidents.

Key Points: 
  • Garnett Station Partners (“Garnett Station”), a New York-based principal investment firm that manages over $2.3 billion of assets, today announced the launch of Accident Care Alliance (“ACA”), a highly specialized platform comprised of best-in-class healthcare providers focused on delivering holistic, individualized care for those injured primarily in automobile accidents.
  • ACA partners with and grows industry-leading healthcare providers that support an underserved population of individuals injured in automobile accidents and are in need of adequate access to timely, premium healthcare services.
  • “We are building ACA around delivering convenient access and exceptional services to patients who lack access to best-in-class treatment options.
  • Rafi Haramati, Principal at Garnett Station, added, “The accident injury healthcare market is highly fragmented and growing, and with over half of accident injury cases in the United States resulting from automobile accidents, we see a great opportunity to build the leading platform to help improve the services available to injured patients.

Heliogen, Inc. Announces Fourth Quarter and Full Year 2023 Financial and Operational Results; Appoints New CFO

Retrieved on: 
Monday, March 25, 2024
Alternative Energy, Energy, Other Energy, Utilities, Hydrogen, SunEdison, Risk management, Growth, Ross School, Business, Telephone, Webcast, TBI, Middlebury College, EDT, University, Treasurer, Senior, MBA, Investment, Event, Interim, CSP, Woodside Energy, Capella, Renewable energy

Heliogen, Inc. (“Heliogen”) (OTCQX: HLGN), a leading provider of AI-enabled concentrating solar energy technology, today provided its fourth quarter and full year 2023 financial and operational results and announced the appointment of its new Chief Financial Officer.

Key Points: 
  • Heliogen, Inc. (“Heliogen”) (OTCQX: HLGN), a leading provider of AI-enabled concentrating solar energy technology, today provided its fourth quarter and full year 2023 financial and operational results and announced the appointment of its new Chief Financial Officer.
  • Previously, he served as Senior Vice President and Treasurer of True Blue, Inc. (NYSE: TBI) from November 2016 to March 2022.
  • Heliogen’s Adjusted EBITDA was $(23.9) million and $(79.2) million for the fourth quarter and full year 2023, respectively.
  • The Heliogen management team will host a conference call to discuss its fourth quarter and full year 2023 financial results on Tuesday, March 26, 2024, at 10:00 a.m. EDT.

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Retrieved on: 
Monday, March 18, 2024
Pharmaceutical, Health, Neurology, Clinical Trials, Depression, Metabolism, Brain, NCE, Acute stress disorder, Concussion, Veterans' affairs, Executive, Common, Inflammation, Patient, United States Congress, TBI, Foundation (nonprofit), Anxiety, CTE, University, Military personnel, Oxidative stress, Human, GMP, Nasal cavity, Traumatic brain injury, DSM-IV codes, Phase, Traffic, Swelling, FDA, Animal, Pentagon, Chronic traumatic encephalopathy, Phase II, Marcus Foundation, Medical device

Oragenics’ lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion.

Key Points: 
  • Oragenics’ lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion.
  • Dr. Kelly was also National Director of the Avalon Action Alliance TBI Programs for which the MIBH serves as the clinical coordinating center.
  • “I am excited to join Oragenics as its Chief Medical Officer at such an important and pivotal time in the drug development process.
  • Dr. Kelly has interacted with the FDA and clinical trials for brain injury throughout his esteemed career.